Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022229685> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2022229685 endingPage "386" @default.
- W2022229685 startingPage "381" @default.
- W2022229685 abstract "Study objective. To determine the tolerability of rituximab, specifically cytokine release syndrome/acute infusion reactions (CRS), when it is administered before or after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in patients with non-Hodgkin’s lymphoma (NHL). Methods. This study is a retrospective analysis of patients identified through pharmacy chemotherapy records. Inclusion criteria were diagnosis of NHL, first cycle of rituximab with CHOP or modified CHOP (mCHOP), treated between 1/1/04 and 6/30/09, age 18 years and greater, and inpatient status. Patients were excluded if their records/information were unavailable. Patients were divided into two groups based on practices observed at our institution: rituximab followed by CHOP (R-CHOP) or CHOP followed by rituximab (CHOP-R). Patient records were reviewed to determine demographic data, CRS, vital signs, evidence of chills/rigors, use of rescue medications, and rituximab infusion rates. Results. One-hundred thirteen patients meeting the inclusion criteria were divided into two groups: R-CHOP ( n = 29) and CHOP-R ( n = 84). R-CHOP patients experienced numerically more CRS (65.5% vs. 42.9%, p = 0.0517) and significantly more chills/rigors ( p = 0.0376). Maximum and minimum oxygen (O 2 ) saturations were significantly lower in the R-CHOP group ( p = 0.0444 and 0.0165, respectively). Maximum temperature was significantly higher in the R-CHOP group ( p = 0.0047). There was no difference between groups in use of rescue medications ( p = 1). R-CHOP patients required significantly more rate reductions ( p = 0.0431) than CHOP-R patients, although there was no difference in final tolerated rate between groups. Conclusions. Patients with NHL who receive rituximab after CHOP experience significantly fewer chills/rigors, higher oxygen saturations, lower maximum temperatures, and fewer rate reductions than patients who receive rituximab before CHOP." @default.
- W2022229685 created "2016-06-24" @default.
- W2022229685 creator A5040376307 @default.
- W2022229685 creator A5090397460 @default.
- W2022229685 date "2010-11-25" @default.
- W2022229685 modified "2023-09-27" @default.
- W2022229685 title "Rituximab tolerability when given before or after CHOP" @default.
- W2022229685 cites W1915689252 @default.
- W2022229685 cites W2004961788 @default.
- W2022229685 cites W2032423298 @default.
- W2022229685 cites W2058015212 @default.
- W2022229685 cites W2101939391 @default.
- W2022229685 cites W2106555579 @default.
- W2022229685 cites W2153665789 @default.
- W2022229685 cites W2164819810 @default.
- W2022229685 doi "https://doi.org/10.1177/1078155210386989" @default.
- W2022229685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21109616" @default.
- W2022229685 hasPublicationYear "2010" @default.
- W2022229685 type Work @default.
- W2022229685 sameAs 2022229685 @default.
- W2022229685 citedByCount "6" @default.
- W2022229685 countsByYear W20222296852013 @default.
- W2022229685 countsByYear W20222296852018 @default.
- W2022229685 countsByYear W20222296852019 @default.
- W2022229685 countsByYear W20222296852022 @default.
- W2022229685 crossrefType "journal-article" @default.
- W2022229685 hasAuthorship W2022229685A5040376307 @default.
- W2022229685 hasAuthorship W2022229685A5090397460 @default.
- W2022229685 hasConcept C126322002 @default.
- W2022229685 hasConcept C197934379 @default.
- W2022229685 hasConcept C2776694085 @default.
- W2022229685 hasConcept C2776755627 @default.
- W2022229685 hasConcept C2778375690 @default.
- W2022229685 hasConcept C2778594517 @default.
- W2022229685 hasConcept C2779338263 @default.
- W2022229685 hasConcept C2779429289 @default.
- W2022229685 hasConcept C2779725641 @default.
- W2022229685 hasConcept C2780653079 @default.
- W2022229685 hasConcept C71924100 @default.
- W2022229685 hasConcept C90924648 @default.
- W2022229685 hasConceptScore W2022229685C126322002 @default.
- W2022229685 hasConceptScore W2022229685C197934379 @default.
- W2022229685 hasConceptScore W2022229685C2776694085 @default.
- W2022229685 hasConceptScore W2022229685C2776755627 @default.
- W2022229685 hasConceptScore W2022229685C2778375690 @default.
- W2022229685 hasConceptScore W2022229685C2778594517 @default.
- W2022229685 hasConceptScore W2022229685C2779338263 @default.
- W2022229685 hasConceptScore W2022229685C2779429289 @default.
- W2022229685 hasConceptScore W2022229685C2779725641 @default.
- W2022229685 hasConceptScore W2022229685C2780653079 @default.
- W2022229685 hasConceptScore W2022229685C71924100 @default.
- W2022229685 hasConceptScore W2022229685C90924648 @default.
- W2022229685 hasIssue "4" @default.
- W2022229685 hasLocation W20222296851 @default.
- W2022229685 hasLocation W20222296852 @default.
- W2022229685 hasOpenAccess W2022229685 @default.
- W2022229685 hasPrimaryLocation W20222296851 @default.
- W2022229685 hasRelatedWork W160156331 @default.
- W2022229685 hasRelatedWork W1986069952 @default.
- W2022229685 hasRelatedWork W2022229685 @default.
- W2022229685 hasRelatedWork W2158035792 @default.
- W2022229685 hasRelatedWork W2178567417 @default.
- W2022229685 hasRelatedWork W2519696495 @default.
- W2022229685 hasRelatedWork W2842555153 @default.
- W2022229685 hasRelatedWork W3089840555 @default.
- W2022229685 hasRelatedWork W2159407751 @default.
- W2022229685 hasRelatedWork W2183308400 @default.
- W2022229685 hasVolume "17" @default.
- W2022229685 isParatext "false" @default.
- W2022229685 isRetracted "false" @default.
- W2022229685 magId "2022229685" @default.
- W2022229685 workType "article" @default.